Study guide

3.5 Therapeutic Drug Monitoring and Clinical Toxicology

Philippine Medical Technologists Licensure Examination MTLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety

1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards

2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function

2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice

3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology

3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology

4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety

4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria

5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology

6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology

6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods

7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods

7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control

8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders

8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry

9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders

9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures

11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions

11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin

12 Chapter 12: Clinical Serology and Immunology

12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology

13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control

14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens

14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens

15 Chapter 15: Histopathologic Techniques and Cytotechnology

15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records

16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics

16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics

3.5 Therapeutic Drug Monitoring and Clinical Toxicology

Key Takeaways Explain This Topic AI

Therapeutic drug monitoring trough specimens are drawn immediately before the next dose, and results are interpretable only after about five half-lives at steady state.

An osmolal gap above about 10 mOsm/kg, measured by freezing-point depression, suggests an unmeasured osmole such as methanol, ethylene glycol, or isopropanol.

Isopropanol poisoning produces ketonemia and ketonuria from acetone without metabolic acidosis, unlike methanol and ethylene glycol.

A presumptive-positive drug immunoassay screen must be confirmed by a compound-specific method such as GC-MS or LC-MS/MS before it is reported as positive.

Organophosphate exposure is assessed by RBC acetylcholinesterase and plasma pseudocholinesterase activity, both of which are depressed.

Last updated: October 2026

Therapeutic Drug Monitoring and Clinical Toxicology

Clinical Chemistry includes endocrinology and toxicology as a tested subtopic. On the MTLE, toxicology questions combine chemistry (which method, which specimen, which interference) with patient safety (chain of custody, antidote timing, critical values). This section begins with therapeutic drug monitoring and common acute poisonings, then covers alcohols and the osmolal gap, drugs of abuse testing, heavy metals, pesticides, and cyanide.

1. Therapeutic Drug Monitoring (TDM) and Common Acute Poisonings

Therapeutic Drug Monitoring (TDM) involves measuring circulating drug concentrations to personalize dosing regimens for pharmaceuticals characterized by a narrow therapeutic index (where the effective therapeutic concentration is close to the toxic concentration).

Pharmacokinetic Fundamentals

Steady-State Concentration ( C s s C_{ss} C ss ​ ): Occurs when the rate of drug administration equals the rate of drug elimination. Achieving steady state requires 5 to 7 elimination half-lives ( t 1 / 2 t_{1/2} t 1/2 ​ ) following initiation of therapy or dosage adjustment. TDM sampling is uninterpretable until steady state is reached.

Sample Timing:

Trough Concentration: Drawn immediately prior to the next scheduled dose (within 15-30 minutes before administration). Represents the lowest drug concentration in the dosing interval; critical for assessing therapeutic efficacy and avoiding accumulation toxicity.

Peak Concentration: Drawn after drug distribution into tissues is complete ( distribution equilibrium ). For intravenous infusions, drawn 30 to 60 minutes post-infusion ; for oral medications, drawn 1 to 2 hours post-ingestion .

Critical Monitored Drugs

Drug Class & Name Therapeutic Range Primary Toxicities & Clinical Monitoring Points

Gentamicin / Tobramycin (Aminoglycosides) Peak: 5 − 10 μ g/mL 5 - 10\text{ }\mu\text{g/mL} 5 − 10 μ g/mL ; Trough: < 2.0 μ g/mL < 2.0\text{ }\mu\text{g/mL} < 2.0 μ g/mL Inhibit bacterial 30S ribosomes; bactericidal concentration-dependent killing. High troughs ( > 2.0 μ g/mL >2.0\text{ }\mu\text{g/mL} > 2.0 μ g/mL ) cause severe ototoxicity (irreversible vestibular/auditory nerve damage) and nephrotoxicity (acute tubular necrosis).

Vancomycin (Glycopeptide) Trough: 10 − 20 μ g/mL 10 - 20\text{ }\mu\text{g/mL} 10 − 20 μ g/mL (15-20 for severe MRSA); current consensus prefers AUC-guided dosing (AUC 400-600) Inhibits cell wall synthesis. Trough monitoring prevents nephrotoxicity and ototoxicity. Red Man syndrome is an infusion-rate-dependent histamine release, not true toxicity.

Digoxin (Cardiac Glycoside) 0.8 − 2.0 ng/mL 0.8 - 2.0\text{ ng/mL} 0.8 − 2.0 ng/mL ( 1.0 − 2.6 nmol/L 1.0-2.6\text{ nmol/L} 1.0 − 2.6 nmol/L ) Inhibits myocardial N a + / K + Na^+/K^+ N a + / K + -ATPase. Narrow therapeutic index. Hypokalemia and hypomagnesemia strongly potentiate digoxin toxicity by enhancing drug binding to the ATPase pump. Signs: visual halos (xanthopsia), nausea, lethal ventricular arrhythmias. Specimen must be drawn ≥ 8 hours \ge 8\text{ hours} ≥ 8 hours post-dose to allow tissue distribution.

Lithium (Mood Stabilizer) 0.6 − 1.2 mmol/L 0.6 - 1.2\text{ mmol/L} 0.6 − 1.2 mmol/L (Toxicity > 1.5 >1.5 > 1.5 ) Used in bipolar affective disorder. Eliminated almost entirely by the kidneys; filtered lithium is reabsorbed in the proximal tubule alongside sodium. Hyponatremia or dehydration decreases lithium clearance, inducing toxicity (tremor, ataxia, lethargy, seizures).

Phenytoin (Dilantin) (Anticonvulsant) Total: 10 − 20 μ g/mL 10 - 20\text{ }\mu\text{g/mL} 10 − 20 μ g/mL ; Free: 1 − 2 μ g/mL 1 - 2\text{ }\mu\text{g/mL} 1 − 2 μ g/mL Displays non-linear Michaelis-Menten elimination kinetics (metabolism saturates at therapeutic doses; small dose increases produce massive concentration spikes). 90% bound to albumin; in hypoalbuminemia or uremia, total phenytoin is misleadingly low while free active phenytoin may be toxic.

Theophylline (Bronchodilator) 10 − 20 μ g/mL 10 - 20\text{ }\mu\text{g/mL} 10 − 20 μ g/mL (Neonatal apnea: 5 − 10 5-10 5 − 10 ) Phosphodiesterase inhibitor. Toxicity ( > 20 μ g/mL >20\text{ }\mu\text{g/mL} > 20 μ g/mL ) causes cardiac arrhythmias, persistent tachycardia, and intractable seizures.

Carbamazepine (Anticonvulsant) 4 − 12 μ g/mL 4 - 12\text{ }\mu\text{g/mL} 4 − 12 μ g/mL Induces its own hepatic metabolism (autoinduction). Toxicity causes diplopia, ataxia, leukopenia, and aplastic anemia.

Clinical Toxicology

Acetaminophen (Paracetamol) Toxicity: Acetaminophen is metabolized primarily by hepatic glucuronidation and sulfation. In overdose, these pathways saturate, shunting excess drug to cytochrome P450 (CYP2E1), producing the highly reactive, electrophilic intermediate N N N -acetyl- p p p -benzoquinone imine (NAPQI) . NAPQI depletes protective hepatic glutathione stores and binds covalently to hepatocyte macromolecules, causing massive centrilobular hepatic necrosis. Serum concentrations drawn 4 to 24 hours post-ingestion are plotted on the Rumack-Matthew Nomogram to predict hepatotoxicity. Antidote: N N N -acetylcysteine (NAC) , which serves as a glutathione precursor and glutathione substitute, neutralizing NAPQI; most effective when started within 8 hours of ingestion.

Salicylate (Aspirin) Toxicity: Toxic ingestions stimulate the medullary respiratory center (producing an initial respiratory alkalosis ) and uncouple mitochondrial oxidative phosphorylation (accumulating lactate, pyruvate, and acetoacetate, generating a high anion gap metabolic acidosis ). The classic presentation in adults is a mixed respiratory alkalosis and metabolic acidosis. Monitored via the Trinder reaction (ferric nitrate forms a purple chromogen).

Carbon Monoxide (CO): Measured directly as carboxyhemoglobin (COHb) via multi-wavelength co-oximetry. Normal nonsmokers have <1.5-2% COHb; smokers have 4-9%; toxicity manifests at >15-20% (headache, dizziness, nausea); lethal at >50%. Antidote is 100% normobaric or hyperbaric oxygen, which shortens COHb half-life from 320 minutes (room air) to 80 minutes (100% O 2 O_2 O 2 ​ ) or 20 minutes (hyperbaric chamber).

  • 2. Alcohols and the Osmolal Gap
  • Ethanol

Enzymatic method: Alcohol dehydrogenase (ADH) oxidizes ethanol to acetaldehyde while reducing NAD+ to NADH. The rise in absorbance at 340 nm is proportional to the ethanol concentration. Headspace gas chromatography is the forensic reference method.

Specimen rules: Clean the venipuncture site with povidone-iodine or soap and water, not an alcohol pad. Keep the tube stoppered and fill it, because ethanol is volatile. Serum or plasma ethanol is about 1.1 to 1.2 times whole-blood ethanol because serum contains more water, so a medicolegal report must state the specimen type.

Philippine law: The Anti-Drunk and Drugged Driving Act of 2013 (RA 10586) and its implementing rules use a blood alcohol concentration of 0.05% for drivers of private vehicles of up to 4,500 kg gross weight, and 0.0% for drivers of trucks, buses, motorcycles, and public utility vehicles.

Osmolal Gap

Calculated osmolality = 2 [ Na + ] + glucose (mg/dL) 18 + BUN (mg/dL) 2.8 \text{Calculated osmolality} = 2[\text{Na}^+] + \frac{\text{glucose (mg/dL)}}{18} + \frac{\text{BUN (mg/dL)}}{2.8} Calculated osmolality = 2 [ Na + ] + 18 glucose (mg/dL) ​ + 2.8 BUN (mg/dL) ​

Osmolal gap = measured osmolality − calculated osmolality. A gap above about 10 mOsm/kg suggests unmeasured osmoles such as ethanol, methanol, ethylene glycol, isopropanol, or mannitol.

Measure with a freezing-point depression osmometer. A vapor-pressure osmometer does not detect volatile alcohols and will miss the gap.

Ethanol raises the measured osmolality by about 1 mOsm/kg for every 3.7 to 4.6 mg/dL, so subtract its expected contribution before blaming a toxic alcohol.

Toxic Alcohols

Alcohol Toxic Metabolite Key Laboratory Clues Notes

Methanol Formaldehyde → formic acid High osmolal gap early; high anion gap metabolic acidosis later Optic nerve injury and blindness; outbreaks in the Philippines have been linked to methanol-contaminated lambanog

Ethylene glycol (antifreeze) Glycolic acid → oxalic acid High osmolal gap, high anion gap acidosis, acute kidney injury, calcium oxalate crystals in urine Monohydrate crystals are needle or dumbbell shaped; dihydrate crystals look like envelopes

Isopropanol (rubbing alcohol) Acetone High osmolal gap with ketonemia and ketonuria but no acidosis Acetone gives a positive nitroprusside ketone test

Fomepizole (or ethanol) blocks alcohol dehydrogenase so methanol and ethylene glycol are not converted to their toxic acids; hemodialysis removes both the parent alcohol and its acids.

3. Drugs of Abuse: Screening, Confirmation, and Specimen Integrity

Screening uses immunoassays (automated EMIT or CEDIA methods, or lateral-flow cassettes) with a cutoff concentration. Results are reported as negative or presumptive positive.

Cross-reactivity limits screening specificity. Examples: pseudoephedrine and other sympathomimetics in amphetamine assays, and poppy seeds in opiate assays. A presumptive positive therefore needs confirmation by a method that identifies the specific compound, such as GC-MS or LC-MS/MS , usually at a lower cutoff than the screen.

Analytes measured in urine:

  • Drug Main Urinary Target Approximate Detection Window
  • Methamphetamine ("shabu") Methamphetamine and its metabolite amphetamine About 2 to 4 days

Cannabis 11-nor-9-carboxy-THC (THC-COOH) About 3 days after occasional use; several weeks in chronic heavy users

Cocaine Benzoylecgonine About 2 to 4 days

Heroin / morphine Morphine; 6-acetylmorphine is specific for heroin 6-acetylmorphine only for hours; morphine about 2 to 3 days

Specimen validity: The collector checks temperature within 4 minutes of voiding and inspects color and volume. The laboratory tests creatinine, specific gravity, pH, and oxidants. Low creatinine and low specific gravity suggest dilution or substitution; abnormal pH, nitrites, or oxidizing agents suggest adulteration.

Chain of custody: Every transfer of the specimen, from collection through sealing with tamper-evident tape, transport, accessioning, aliquoting, and testing, is documented with date, time, and signatures on the custody and control form. A break in the chain can invalidate a legally defensible result. RA 9165 requirements for Philippine drug testing laboratories are covered in the related-laws section.

  • 4. Heavy Metals, Pesticides, and Cyanide
  • Lead

Specimen: Whole blood in a trace-element-free EDTA tube (royal blue or tan top). Methods include graphite furnace atomic absorption, inductively coupled plasma mass spectrometry (ICP-MS), and anodic stripping voltammetry for point-of-care testing.

Biochemistry: Lead inhibits delta-aminolevulinic acid dehydratase (urine ALA rises) and ferrochelatase (zinc protoporphyrin rises). It also inhibits pyrimidine 5'-nucleotidase, which produces coarse basophilic stippling on the blood smear, and it causes a microcytic anemia.

Interpretation: No blood lead level is considered safe for children. The US CDC lowered its blood lead reference value for children to 3.5 µg/dL in 2021.

Mercury and Arsenic

Mercury: Inorganic and elemental mercury are monitored in urine (preferably 24-hour); methylmercury from fish is monitored in whole blood. Artisanal small-scale gold mining, which uses mercury to amalgamate gold, is a recognized exposure source in the Philippines.

Arsenic: Urine is the preferred specimen for recent exposure. Speciation separates nontoxic seafood arsenic (arsenobetaine) from toxic inorganic arsenic. Hair and nails record chronic exposure, and transverse white nail bands (Mees lines) are a classic sign.

Organophosphate and Carbamate Insecticides

These compounds inhibit acetylcholinesterase , so acetylcholine accumulates and produces a cholinergic crisis: miosis, salivation, lacrimation, bronchorrhea, bradycardia, vomiting, diarrhea, and muscle fasciculations.

Laboratory tests:

RBC (true) acetylcholinesterase reflects the synaptic enzyme and is the better marker of the severity of exposure.

Plasma pseudocholinesterase (butyrylcholinesterase) falls faster and is a sensitive early marker, but it is less specific because liver disease, pregnancy, malnutrition, and inherited variants also lower it.

Treatment: Atropine, plus an oxime such as pralidoxime for organophosphates. Carbamate inhibition is spontaneously reversible.

Cyanide

Cyanide inhibits cytochrome c oxidase , so cells cannot use oxygen. The result is a severe lactic acidosis with high venous oxygen content. Sources include smoke from burning plastics and wool, improperly processed cassava, and sodium nitroprusside infusions.

Whole-blood cyanide results take too long to guide emergency care, so a high lactate in a smoke-inhalation victim prompts empirical treatment with hydroxocobalamin , which binds cyanide to form cyanocobalamin.

5. Toxicology Quick Reference

Toxin Preferred Specimen Key Laboratory Finding Antidote / Key Treatment

Acetaminophen Serum 4 to 24 hours after ingestion Level plotted on the Rumack-Matthew nomogram; rising ALT and AST N-acetylcysteine

Salicylate Serum Respiratory alkalosis plus high anion gap metabolic acidosis Urine alkalinization; hemodialysis when severe

Carbon monoxide Whole blood for co-oximetry Elevated carboxyhemoglobin; pulse oximetry falsely normal 100% or hyperbaric oxygen

Methanol / ethylene glycol Serum High osmolal gap, then high anion gap acidosis; oxalate crystals with ethylene glycol Fomepizole; hemodialysis

Lead Whole blood (trace-element-free EDTA) Basophilic stippling; high zinc protoporphyrin Chelation (succimer, calcium disodium EDTA)

Organophosphates Whole blood for RBC acetylcholinesterase; plasma for pseudocholinesterase Depressed cholinesterase activity Atropine and pralidoxime

Cyanide Whole blood Severe lactic acidosis with high venous oxygen Hydroxocobalamin